✔️ @themotleyfool - @TMFStockAdvisor & @TMFRuleBreakers services
✔️ @7investing
✔️ @investing_city
https://t.co/9aUK1Tclw4
✔️ @MorningstarInc Premium
✔️ @SeekingAlpha Marketplaces (Check your area of interest, Free trials, Quality, track record...)
Happy Holidays\U0001f384\u2603\ufe0fto all, especially to ppl behind these awesome Podcasts\U0001f399\ufe0fthat entertained/educated me for countless hrs this yr.@RBIPodcast@MotleyFoolMoney@MFIndustryFocus@InvestLikeBest@7investing@FocusedCompound@investing_city@chitchatmoney@acquirersx@StockDtective
— Ram Bhupatiraju (@RamBhupatiraju) December 25, 2020
SUMMARY: the Oxford/Astra trial examined dosing with gaps between 4-12 wks- although longer gaps appear to be limited mostly to younger participants. There was no difference reported in published data between these & efficacy from the 1st dose seems high for severe disease.
— Deepti Gurdasani (@dgurdasani1) December 31, 2020
Discussions of 1 vs 2 doses suggest many are not aware of Pfizer's trials which evaluated 1 vs 2 dose immunogenicity, assessed multiple formulations (BNT162b1 BNT162b2 etc) & conducted dose-ranging in both young & old adults at the start. Saw "clear benefit of booster at day 21" pic.twitter.com/mpyxu9xFSF
— Dr Nicole E Basta (@IDEpiPhD) December 31, 2020